Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Clinical trial NCT07733050 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07733050
- Sponsor
- Shanghai General Hospital, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2027-08-01
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.